Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Plasma Protein Therapeutics Industry?
In recent years, the market size of plasma protein therapeutics has seen robust growth. Its growth will rise from $32.22 billion in 2024 to $34.68 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. The historical growth of this market is linked to factors such as a rise in rare diseases, an increasing elderly population, the worldwide supply of blood plasma, an increase in hemophilia cases, enhancements in diagnostic procedures, and a conducive regulatory environment.
It is anticipated that the plasma protein therapeutics market’s size will robustly grow in the coming years. The market is projected to reach “$45.58 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The surge in size during the forecast period can be associated with developments in gene therapy, increased spending in healthcare, broader application areas, precision medicine techniques, and patient accessibility programs. Noteworthy tendencies in the forecast era involve technological revolutions, adoption of telemedicine, advancements in plasma fractionation technology, the creation of next-generation therapies, acceptance of recombinant therapies, and personalized medicine strategies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp
What Forces Are Driving The Growth Of The Plasma Protein Therapeutics Industry?
The rise in autoimmune disorders is anticipated to fuel the expansion of the plasma protein therapeutics market. Autoimmune disorders occur when the body’s immune system mistakenly attacks and destroys healthy cells. Autoimmune diseases, which develop when the body erroneously identifies a part of itself as alien and creates proteins (autoantibodies) that assault the misinterpreted part of the body, are treated with therapeutic plasma exchange. For example, research involving 22 million people undertaken by the University of Glasgow, a public university in the UK, discovered in May 2023 that approximately 10% of the UK’s population suffers from autoimmune disorders, surpassing previous predictions. As a result, the growing incidence of autoimmune disorders is propelling the advancement of the plasma protein therapeutics market.
What Is The Overview Of Market Segmentation In The Plasma Protein Therapeutics Industry?
The plasma protein therapeutics market covered in this report is segmented –
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications
Subsegments:
1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Albumin: Human Serum Albumin, Recombinant Albumin
3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates
4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors
5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates
Which Trends Are Redefining The Future Landscape Of The Plasma Protein Therapeutics Industry?
Innovations in product development are becoming increasingly prevalent in the plasma protein therapeutics market, constituting a key trend. Many prominent companies in this sector are leveraging novel products to maintain a competitive edge in the market. One such example can be found in Octapharma AG, a Swiss enterprise that in October 2023, had received the green light from European medical bodies for its lyophilized version of their renowned product, octaplasLG. Constructed for pre-hospital transfusions, this advanced product offers healthcare providers an efficient and pragmatic solution for handling patients during emergencies. This approval emphasizes Octapharma’s dedication to augmenting patient care by pioneering innovative blood product solutions.
Who Are The Primary Players Operating Across The Global Plasma Protein Therapeutics Market?
Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report
Which Region Offers The Most Growth Potential For The Plasma Protein Therapeutics Market Through 2029?
North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model